Amongst other complications of Diabetes, Diabetic foot ulcer is the most common complication seen in India. Apart from the fact that diabetic foot ulcers are non-healing, they not only hamper the Quality of life of the patient but may also lead to many complications, all leading to a total or partial foot amputation. Centaur Pharmaceuticals launched a New Chemical Entity (NCE) – WOXheal. With its dual mechanism of action, WOXheal is a unique product in the treatment of Diabetic Foot ulcers. WOXheal will be readily available in the entire country by the end of the month. A globally patented product, WOXheal topical solution, is effective in treating diabetic foot ulcers. This pioneering effort by Centaur Pharmaceuticals, for an unmet medical need, enhances India’s stature as a self-reliant nation and a Pharma super-power.
“We, at Centaur Pharmaceuticals, were deeply concerned with the alarming rate of foot amputations in India, and wanted to discover a drug to prevent it. Fifteen years ago, we collaborated with CytoTools AG, Germany, who had this promising molecule for the treatment of Diabetic foot ulcers. We are very happy to offer this ray of hope to people with Diabetic foot ulcer in India”, said Mr. S. D. Sawant, Chairman and MD of Centaur Pharmaceuticals.
